Halifax, Nova Scotia–(Newsfile Corp. – October 16, 2020) – Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: ATURF) (FSE: AHUH) (“Sixth Wave” or the “Company”) is pleased to provide an update on the Company’s growing patent portfolio.
The Company received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) for patent application No. 15/747,858. The patent application was for the Company’s molecularly imprinted polymer beads for the extraction of metals and uses thereof. The aforementioned patent will issue on October 27, 2020 as U.S. Patent No. 10,814,306. With the issue of this patent the Company has broadened the Company’s already registered patent No. 9,504,988 which is also for the use of the Company’s molecularly imprinted polymer beads for the extractions of metals and uses thereof.
The Company has already completed the development and productization of its IXOS® product line for the extraction of gold and silver which represents the first of its embodiments of the aforementioned patents.
In addition to the Company’s registered and patent pending patent portfolio covering the extraction of metals and uses there of the Company has filed applications for patents pertaining to its other technology applications as summarized below:
On April 3, 2020, the Company announced that it had filed Patent Application Number 63000977 – “The Use of Molecularly Imprinted Polymers for the Rapid Detection of Emerging Viral Outbreaks” with the US Patent and Trademark Office. This application covered the use of molecularly imprinted polymers for the detection of emerging viral strains such as SARS-CoV-2 and marked the Company’s entrance in the virus detection sector. Further patent protection was applied for on April 17, 2020 with the filing of Patent Application Number 63010244. This second application covered application devices which would incorporate the proposed viral detection technology in a variety of applications, including the company’s proposed Smartmask™.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure, or contain the COVID-19 (or SARS-CoV-2 coronavirus) at this time. The Company has completed the first phases of development of virus detection polymer embodied in this set of patents under the Accelerated Molecularly Imprinted Polymers (AMIPS™) brand name.
On March 12, 2020, the Company filed Patent Application Number PCT/US2020/022427 for the use of molecularly imprinted polymers for extraction of cannabinoids and uses thereof. This patent application covers the Company’s Affinity™ molecularly imprinted polymer technology that is being used in the Company’s Affinity™ Cannabinoid extraction systems. The Affinity™ product line is in the final phases of commercialization and optimization with the expected delivery of its first fully functional revenue generating system before the end of the year with full roll out in first quarter 2021.
As noted by Dr. Jonathan Gluckman, President and CEO of SIXW, “The Company is developing a strong history of being awarded patent protection worldwide as evidenced in part with this new issuance. It remains a core priority for the Company to continue to develop new intellectual property to reflect the growing commercial needs for extraction, diagnostic, and purification solutions. Reduction to practice and commercial sales of products utilizing the Company’s patents add significant value to the shareholders and helps solidify the Company’s position as a leader in this field of nanotechnology.”
The Company further reports that it has implemented an employee equity participation plan. The plan, which is voluntary, permits employees to receive compensation in the form of common shares of the company in lieu of a portion, or all, of the employee’s cash compensation. The Company has issued a total of 2,016,240 common shares at a price of $0.30 per share representing significant participation by management and key employees. The Company further reports that is has granted a total of 1,150,000 options to directors, employees, advisory board members, and consultants. The options are exercisable at a price of $0.35 per share and will expire on October 16, 2025. One third of the options will vest after six months, with a further third vesting every six months thereafter. Lastly, the company has issued 2,000,000 Deferred Share Units under its Deferred Share Unit Plan.
About Sixth Wave
Sixth Wave is a development stage nanotechnology company with patented and patent-pending technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Accelerated Molecularly Imprinted Polymers (AMIPs™). The Company is in the process of commercializing its Affinity™ cannabinoid purification system, as well as, IXOS®, a line of extraction polymers for the gold mining industry.
Sixth Wave can design, develop and commercialize AMIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for detection and separation of viruses, biogenic amines and other pathogens, for which the Company has products at various stages of development.
For more information about Sixth Wave, please visit our web site at: www.sixthwave.com
ON BEHALF OF THE BOARD OF DIRECTORS
Jonathan Gluckman, Ph.D., President & CEO
For information, please contact the Company:
Phone: (801) 582-0559
This press release includes certain statements that may be deemed “forward-looking statements” including statements regarding the planned features, capacity and performance of the AMIPs™ technology and the planned Air Monitoring System. All statements in this release, other than statements of historical facts, that address future events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual events or developments may differ materially from those in forward-looking statements. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause the Company’s actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. In particular, successful development and commercialization of the AMIPs™ technology are subject the risk that the AMIPs™ technology may not prove to be successful in detecting virus targets effectively or at all, uncertainty of medical product development, uncertainty of timing or availability of required regulatory approvals, lack of track record of developing products for medical applications and the need for additional capital to carry out product development activities. The value of any products ultimately developed could be negatively impacted if the patent is not granted. The Company has not yet completed development of a prototype for the product that is subject of its patent application and has not yet applied for regulatory approval for the use of this product from any regulatory agency.
NOT FOR DISTRIBUTION IN THE U.S. OR OVER U.S.NEWSWIRES
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66189
PURA 1-for-1 Shareholder Dividend of PAOG Shares on Track
Dallas, Texas–(Newsfile Corp. – October 30, 2020) – PAO Group, Inc. (OTC Pink: PAOG) and Puration, Inc. (OTC: Pink: PURA) today released an update on the process underway for PAOG to issue PAOG shares to PURA shareholders in a dividend distribution.
PAOG acquired a cannabis cultivation operation from PURA earlier this year in a transaction that includes issuing PAOG shares to PURA shareholders. The target distribution ratio calls for PURA shareholders receiving one share of PAOG for every one share of PURA owned.
PAOG has executed two acquisitions in recent months and managed to ramp up and organize acquired cannabis pharmaceutical research assets as necessary to execute a contract prerequisite to developing its acquired cannabis pharmaceutical research assets into an FDA approved drug. PAOG admits the dividend distribution process has lagged behind the acquisition and pharmaceutical development contract efforts. Last week, after completing the pharmaceutical development contract, PAOG management and PURA management committed to rapidly completing the dividend issuance.
Since initiating the joint rapid dividend completion effort, PAOG has filed to redomicile the company to Wyoming and increase the authorized number of shares in order to have the necessary inventory to execute the dividend distribution. PAOG has also engaged the services of the company’s transfer agent to manage the dividend distribution of PAOG stock to PURA shareholders. Once the move to Wyoming is complete, PAOG will file with the necessary financial regulatory authority to finalize the dividend details. PAOG anticipates a definitive dividend distribution announcement will be forthcoming within the next two weeks.
PAOG is excited to make PURA shareholders also PAOG shareholders.
The developing PAOG and PURA partnership includes PAOG participating in PURA’s new hemp lifestyle brand strategy, called Farmersville Brands and headquartered on a 72-acre property currently under contract for acquisition by PURA. In conjunction with PAOG’s newly acquired cultivation business, PAOG plans to build a pharmaceutical grade, indoor hemp cultivation operation and lab on PURA’s Farmersville property.
Look for more information coming soon from both PURA and PAOG.
For more information on PAO Group, visit www.paogroupinc.com.
For more information on Puration, visit www.purationinc.com.
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
PAO Group, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67197
Early Warning Report in Connection with the Sale of 5,500,000 Subordinate Voting Shares of Green Thumb Industries Inc.
Chicago, Illinois–(Newsfile Corp. – October 30, 2020) – On October 29, 2020, RCP23, LLC (the “Seller”), a private investment holding company controlled by Benjamin Kovler, CEO and Chairman of Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) (the “Issuer”), sold 5,500,000 Subordinate Voting Shares of the Issuer (the “Transferred Shares”) to a third-party qualified institutional buyer at a purchase price of C$19.25 per share in a private transaction. Prior to the sale, at Seller’s request, the Issuer converted 54,805 Super Voting Shares and 49,448 Multiple Voting Shares of the Issuer previously held by the Seller into an aggregate 10,425,300 Subordinate Voting Shares per the terms of the Issuer’s Articles of Incorporation, as amended.
Following the sale, Mr. Kovler, together with his joint actors, holds beneficial ownership or control or direction over 183,254 Super Voting Shares, which represent 56.5% of the class, 0 Multiple Voting Shares, and 5,068,016 Subordinate Voting Shares, which represent less than 2.9% of the class. Each Super Voting Share carries 1,000 votes and is convertible into one Multiple Voting Share and each Multiple Voting Share carries 100 votes and is convertible into 100 Subordinate Voting Shares (each of which carries one vote).
For further information, please contact Investor Relations, Green Thumb Industries Inc., InvestorRelations@GTIgrows.com, Phone: 310-622-8257.
This press release is issued pursuant to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, which requires an early warning report to be filed on SEDAR (www.sedar.com) containing additional information with respect to the foregoing matters. A copy of this report may be obtained by contacting Investor Relations, Green Thumb Industries Inc., InvestorRelations@GTIgrows.com, Phone: 310-622-8257.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67179
Special Guests and Lovers of Psychedelics Are “Coming Out of the Chemical Closet” to Celebrate New Book about MDMA — Register For Virtual Book Launch
New York, New York–(Newsfile Corp. – October 30, 2020) – Charley Wininger and his publisher Inner Traditions are welcoming the arrival of his book “Listening to Ecstasy: The Transformative Power of MDMA” with a free virtual night of storytelling on Nov 13th, 7:00 PM (Eastern Time). Members of the press are invited to join this unique event. To register click link HERE.
To view an enhanced version of this graphic, please visit:
Charley will be joined by several psychedelic luminaries, and hosted by comedian Sarah Rose Siskind. They will share intimate, touching and humorous stories about a time their lives were transformed by the often misunderstood underground party drug, MDMA.
In his book, “Listening to Ecstasy” Charley reveals how MDMA has enhanced his marriage both erotically and emotionally, and describes how pleasure, fun, and joy can be profound bonding and transformative experiences.
To view an enhanced version of this graphic, please visit:
“This is also the story of how my wife and I entered a forbidden world of drug users, and found it to be enchanted. MDMA opened up our lives to new friends, fun, and freedom. It’s also helped us navigate the aging process as we transitioned from middle age into our sixties and seventies.” – Charley Wininger
Wininger’s writing and personal narrative shows how MDMA can be a tool for healing and connection. This is why this particular psychedelic compound is being studied to treat Post-Traumatic Stress Disorder (PTSD) with Phase 3, peer-reviewed trials taking place at research sites in the U.S., Canada, and Israel. (Multidisciplinary Association for Psychedelic Studies, 2020). At the current pace, MDMA will be a prescription medication in the U.S. by 2023.
In a recent Forbes article, Charley referred to MDMA as “super glue for relationships“. He and his wife are open to giving candid interviews about how MDMA helps to strengthen their connection.“It can help you connect with yourself, with your loved ones and with the world at large, [which] is especially important now when we live in a time of isolation and fear.” – Charley Wininger (Forbes)
Members of the media
- Check out the Charley Wininger Media Kit for quotes and downloadable images
- Book interview with Charley before launch (Nov. 13th)
- Request media review copy of Listening to Ecstasy
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67182
Cannabis3 weeks ago
Bud & Tender® raise testing and quality standards for best CBD oil in the UK
Cannabis3 weeks ago
The World’s Greatest Weight Loss Secret May be Psilocybin
Cannabis2 weeks ago
Aither Ingredients Announces Joint Venture With Thar Process Intended to Disrupt the Canadian Cannabis-based Ingredient Market
Cannabis4 weeks ago
WeedMD Reports Second Quarter 2020 Financial Results and Closes $30 Million Credit Facility with LiUNA Pension Fund
Cannabis4 weeks ago
PAOG Engages Saul Kaye, Founder of iCAN: Israel-Cannabis and CannaTech to Prepare RespRx for IND
Cannabis2 weeks ago
IGNITE Files Q2 2020 Financial Statements and MD&A
Cannabis3 weeks ago
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Files Patent for World’s First Face Mask Designed to Capture SARS-CoV-2 (COVID-19)
Cannabis2 weeks ago
Next Green Wave Sauce Carts Sell Over 100k In Under 30 Days